ClinicalTrials.gg
CompletedNCT07777640Updated Aug 20, 2026

Intra-Ovarian PRP Compared With Gonadotropin for Ovarian Response in Letrozole-Resistant PCOS

An interventional study of Autologous Platelet-Rich Plasma (PRP) and Gonadotropin in Polycystic Ovary Syndrome (PCOS), sponsored by Bangladesh Medical University. Completed at 1 site in Bangladesh. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Bangladesh Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Jun 2025, registered Aug 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 12 studies in Polycystic Ovary Syndrome with a site in Bangladesh — 2 open to participants now, 4 under way, none of them phase 3. Polycystic Ovary Syndrome · Bangladesh.

Enrollment
11th of 12
50 · median 67
Started
2025
with 4 others
No phase
7 of 12
2 open now
Registered
11th of 12
by date
Lead sponsor
1 of 12
Bangladesh Medical University

Among the 12 studies in Polycystic Ovary Syndrome with a site in Bangladesh, this one is the 11th largest by enrollment, is one of 5 that started in 2025, is one of 7 with no phase, and was the 11th registered.

Polycystic Ovary Syndrome

958 studies on the registry are indexed under Polycystic Ovary Syndrome; 175 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

2 of the 12 studies in Polycystic Ovary Syndrome with a site in Bangladesh are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Bangladesh have not opened yet or have stopped. Only those recruiting at a site in Bangladesh →

Who these studies take

Of the 119 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 105 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 35 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Polycystic Ovary Syndrome with a site in Bangladesh, or all of them as a file.
02

Study summary

The goal of this randomized clinical trial is to compare autologous platelet-rich plasma (PRP) with gonadotropin for improving ovarian response in women with letrozole-resistant polycystic ovary syndrome (PCOS). Researchers will compare the two treatments to assess ovarian response, ovulation rates, and pregnancy rates. Participants will be randomly assigned to receive either intra-ovarian autologous PRP or gonadotropin treatment and will be followed for three consecutive cycles.

Read the detailed description

Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disorder that may cause anovulation and infertility. Letrozole is a first-line ovulation induction agent; however, a proportion of women with PCOS are resistant to standard-dose letrozole and may require second-line treatment such as gonadotropin therapy. Gonadotropin treatment can be effective but requires monitoring because of the risks of ovarian hyperstimulation and multiple pregnancy. This randomized clinical trial is designed to evaluate and compare the effects of intra-ovarian autologous platelet-rich plasma (PRP) and gonadotropin treatment on ovarian response in women with letrozole-resistant PCOS.

Eligible women attending the Department of Reproductive Endocrinology and Infertility, Bangladesh Medical University, will be identified according to the Rotterdam diagnostic criteria for PCOS and screened according to the study inclusion and exclusion criteria. Participants will receive detailed information about the study and provide written informed consent before enrollment. Sociodemographic information, relevant clinical history, and investigations will be recorded using a structured data collection sheet.

Participants will be randomly allocated into two intervention groups using a computer-generated random number sequence. Participants in the experimental group will receive 5 mL of autologous platelet-rich plasma in each ovary by laparoscopy during the proliferative phase of the menstrual cycle. Following the procedure, participants will be monitored for spontaneous ovulation for three consecutive months.

Participants in the gonadotropin group will receive gonadotropin stimulation for three consecutive cycles. Follicular development will be monitored by transvaginal ultrasonography. Gonadotropin stimulation will be administered according to the study protocol, followed by human chorionic gonadotropin triggering when a mature follicle is identified. Timed intercourse will be advised following triggering. Ovulation will subsequently be assessed by mid-luteal serum progesterone measurement.

Tubal patency will be assessed as part of the infertility evaluation to exclude tubal factor infertility. In participants allocated to the PRP group, tubal evaluation will be performed during the laparoscopic procedure undertaken for intra-ovarian PRP administration. In participants allocated to the gonadotropin group, tubal evaluation will be performed before initiation of gonadotropin stimulation. Participants found to have bilateral tubal block will be excluded from the study.

The primary outcome is ovarian response, assessed by transvaginal ultrasonography, including the proportion of participants developing follicles measuring at least 14 mm, the proportion developing mature follicles measuring 18-25 mm, and endometrial thickness of at least 7 mm. Ovulation rate will be assessed by mid-luteal serum progesterone, with a progesterone concentration greater than 3 ng/mL considered indicative of ovulation. Pregnancy rate will be assessed by serum beta-human chorionic gonadotropin.

Participants will also be monitored for treatment-related adverse effects, including ovarian hyperstimulation syndrome, multiple pregnancy, and injection-site reactions. The study will compare ovarian response, ovulation rate, and pregnancy rate between the intra-ovarian autologous PRP group and the gonadotropin group over three consecutive treatment cycles/months.

The study aims to determine whether intra-ovarian autologous PRP may improve ovarian response and ovulation in women with letrozole-resistant PCOS compared with gonadotropin treatment.

03

Conditions studied

  • Polycystic Ovary Syndrome (PCOS)

Keywords

  • Letrozole-resistant PCOS
  • Autologous platelet-rich plasma
  • Gonadotropin
  • Ovarian response
  • Ovulation
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18-35 years diagnosed with polycystic ovary syndrome (PCOS) based on the Rotterdam criteria.
  • Primary or secondary subfertility.
  • Patients with a history of letrozole resistance (failure to ovulate with standard dose of letrozole).

Exclusion criteria

Exclusion Criteria:

  • (BMI) \<18.5 kg/m² or ≥30 kg/m².
  • Presence of other causes of infertility (e.g., endometriosis, tubal factor, severe male factor infertility).
  • Patients with uncontrolled endocrine disorders (e.g., thyroid dysfunction, hyperprolactinemia).
  • Any to -rich plasma (PRP) therapy (coagulation disorder or current use of anticoagulant).
  • Patient not fit for surgery.
  • to gonadotropin.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Intra-Ovarian Autologous PRP

    Participants will receive intra-ovarian autologous platelet-rich plasma (PRP) by laparoscopy and will be followed for ovarian response, ovulation, and pregnancy outcomes for three consecutive cycles

    Biological: Autologous Platelet-Rich Plasma (PRP)

  • Active comparator
    Gonadotropin

    Participants will receive gonadotropin treatment for three consecutive cycles and will be followed for ovarian response, ovulation, and pregnancy outcomes.

    Drug: Gonadotropin

Interventions

  • BiologicalPlatelet rich plasmaStudies of Platelet rich plasmaPlatelet rich plasma pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will receive 5 mL of autologous platelet-rich plasma (PRP) in each ovary by laparoscopy during the proliferative phase of the menstrual cycle. Following the procedure, participants will be monitored for spontaneous ovulation for three consecutive cycles.

  • DrugGonadotropinsStudies of GonadotropinsGonadotropins pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will receive recombinant follicle-stimulating hormone (rFSH) 75 IU intramuscularly on days 5 and 7 of the menstrual cycle, followed by human menopausal gonadotropin (hMG) 75 IU intramuscularly on days 9 and 11. Follicular development will be monitored by transvaginal ultrasonography. When at least one mature follicle measuring 18-25 mm is identified, ovulation will be triggered with human chorionic gonadotropin (hCG) 5,000 IU intramuscularly, followed by timed intercourse.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With Developing Follicles ≥14 mm

    Developing follicles will be assessed by transvaginal ultrasonography. A follicle measuring ≥14 mm in diameter will be considered a developing follicle.

    Time frame: Day 12 to Day 14 of each treatment cycle, where each treatment cycle is defined as one menstrual cycle from the first day of menstrual bleeding to the first day of the next menstrual bleeding, for up to three consecutive treatment cycles.

  2. Proportion of Participants With Mature Follicles

    Mature follicle will be defined as a follicle measuring 18 to 25 mm in diameter on transvaginal ultrasonography.

    Time frame: Day 12 to Day 14 of each treatment cycle, where each treatment cycle is defined as one menstrual cycle from the first day of menstrual bleeding to the first day of the next menstrual bleeding, for up to three consecutive treatment cycles.

  3. Proportion of Participants With Endometrial Thickness ≥7 mm

    Endometrial thickness will be measured by transvaginal ultrasonography. An endometrial thickness of ≥7 mm will be considered the target response

    Time frame: Day 12 to Day 14 of each treatment cycle, where each treatment cycle is defined as one menstrual cycle from the first day of menstrual bleeding to the first day of the next menstrual bleeding, for up to three consecutive treatment cycles.

  4. Proportion of Participants With Ovulation

    Ovulation will be assessed by mid-luteal serum progesterone measurement. A serum progesterone level \>3 ng/mL will be considered indicative of ovulation

    Time frame: 7 days after ovulation trigger in each treatment cycle, where each treatment cycle is defined as one menstrual cycle from the first day of menstrual bleeding to the first day of the next menstrual bleeding, for up to three consecutive treatment cycles.

Secondary outcomes

  1. Pregnancy Rate

    Pregnancy will be assessed by quantitative serum beta-human chorionic gonadotropin (β-hCG) measurement one week after a missed menstrual period. Clinical pregnancy will be confirmed by transvaginal ultrasonography at 6-8 weeks of gestation

    Time frame: One week after a missed menstrual period in each treatment cycle, where each treatment cycle is defined as one menstrual cycle from the first day of menstrual bleeding to the first day of the next menstrual bleeding, for up to three consecutive treatment

07

Study locations

1 site
  • Department of Reproductive Endocrinology and Infertility, Bangladesh Medical University
    Dhaka, Dhaka Division 1000, Bangladesh
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in May 2026, 11 months.

Of 204 non-industry interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's 11 months is below that.

Counting every sponsor, half of 219 studies reached it within 18 months; a quarter within 7 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2026
First posted
Aug 20, 2026
StartActual
Jun 1, 2025
Primary completionActual
May 20, 2026
CompletionActual
May 28, 2026
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07777640
Lead sponsor
Bangladesh Medical University
Responsible party
Nayma Uddin (MS Phase-B Resident, Reproductive Endocrinology and Infertility, Bangladesh Medical University) — Principal investigator
First posted
Aug 20, 2026
Start date
Jun 1, 2025
Primary completion
May 20, 2026
Completion
May 28, 2026
Last update
Aug 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Platelet rich plasma

Start the discussion